Axiomed Raises $3.6 Million Series D Extension
Cleveland, OH--Axiomed Spine Corporation, manufacturer of the Freedom(c) Lumbar Disc and the Freedom(c) Cervical Disc, has raised $3.6 million in fresh capital as it prepares to file for FDA clearance of its lumbar disc and initiates a European pilot trial of its cervical disc.
The Company's lumbar product received CE clearance in 2009 and is being implanted in patients in England, Germany, and Switzerland. The U.S. lumbar pivotal trial is nearing completion.
The cervical disc received a CE mark in 2012. A European pilot trial is underway with the support of the additional capital raise.
The Company's second-generation Total Disc Replacement (TDR) products are designed to restore the natural function of the spine in patients with degenerative disc disease. They are made of an elastomeric polymer to which Axiomed has exclusive rights, encapsulated in titanium end plates. Read more...
Find Out More About ESP
The ESP team has supported Axiomed through multiple rounds of capital